Tech Company Financing Transactions
Cyllene Therapeutics Funding Round
Cyllene Therapeutics, operating out of Paris, secured $37.5 million from GordonMD Global Investments, M Ventures and Andera Partners.
Transaction Overview
Company Name
Announced On
7/7/2026
Transaction Type
Venture Equity
Amount
$37,500,000
Round
Series C
Investors
GordonMD Global Investments (Lead Investor)
M Ventures (Lead Investor)
Andera Partners (Raphaël Wisniewski)
Bpifrance (Benoît Barteau)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
13 rue Watt
Paris, 75013
France
Paris, 75013
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Cyllene Therapeutics is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. Developing next generation DNA medicines to provide safe, efficacious, and affordable therapies to patients with severe localized chronic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philippe Chambon
Chief Marketing Officer
Cornelia Molkenteller
Chief Operating Officer
Samuel Salot
Chief Scientific Officer
Alberto Epstein
Co-Founder
Pierre Denys
Co-Founder
François Giuliano
Co-Founder
Charles Joussain
VP - Bus. Development
Mikael Contrastin
VP - R & D
Teddy Jégu
VP - R & D
Astrid Valles-Sanchez
Browse more venture capital transactions:
Prev: 7/7/2026: Auxilius venture capital transaction
Next: 7/7/2026: Display.dev venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs